Phase 2 Leukaemia Trial, Recruiting NCT06564493 Sponsor: The First Affiliated Hospital of Zhengzhou University Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06564493
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The participant or their guardian must be willing to voluntarily sign a written consent form agreeing to take part.
  • Participants must be male or female, between 1 and 17 years old (inclusive).
  • Participants must have been diagnosed with acute lymphoblastic leukemia (a type of blood cancer) according to World Health Organization standards.
  • The leukemia must be in complete remission (meaning tests show no signs of active disease) before the transplant takes place.
  • A suitable matched sibling donor must be available, and the participant must be willing to undergo a stem cell transplant from that sibling donor.
  • Participants must have a general health score of 70 or higher on a standard medical scale, meaning they are able to care for themselves and carry out normal daily activities.
  • Heart, liver, kidney, and lung function must all be within acceptable ranges, with no major organ problems (confirm specific test values with the trial site).

Who may not be able to join:

  • People whose leukemia has not reached complete remission before the transplant.
  • People who have chosen a donor other than a matched sibling.
  • People with severe heart, liver, kidney, or lung disease that would make it unsafe to go through the pre-transplant treatment process.
  • People who have an active or hard-to-treat infection, or other serious life-threatening complications.
  • People with a history of another cancer, a psychiatric disorder, or HIV infection.
  • People whose participant or guardian refuses to sign the consent form, is unwilling to attend required follow-up visits, or does not agree to their data being used for future research and reporting.
  • People whom the trial investigators consider unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86037166862278

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The First Affiliated Hospital of Zhengzhou University
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
31 July 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Relapse-free survival (RFS); acute Graft Versus Host Disease (aGVHD); Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov